Onyx Pharmaceuticals (NASDAQ: ONXX) announced its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.76) by $0.40. The company had revenue of $127.90 million for the quarter, compared to the consensus estimate of $113.17 million. During the same quarter last year, the company posted $1.50 earnings per share. Onyx Pharmaceuticals’s revenue was down 46.0% compared to the same quarter last year.
Several analysts have also recently commented on the stock. Analysts at TheStreet reiterated a “hold” rating on shares of Onyx Pharmaceuticals in a research note to investors on Tuesday, February 12th. On the ratings front, analysts at JMP Securities initiated coverage on shares of Onyx Pharmaceuticals in a research note to investors on Friday, February 8th. They set an “outperform” rating and a $100.00 price target on the stock. Finally, analysts at Robert W. Baird cut their price target on shares of Onyx Pharmaceuticals from $99.00 to $96.00 in a research note to investors on Wednesday, January 16th. They now have an “outperform” rating on the stock.
Thirteen investment analysts have rated the stock with a buy rating, two have assigned an overweight rating, and three have given a hold rating to the company’s stock. The company currently has an average rating of “buy” and an average price target of $100.57.
Onyx Pharmaceuticals (ONXX) traded down 3.41% on Thursday, hitting $69.93. Onyx Pharmaceuticals (ONXX) has a 1-year low of $35.73 and a 1-year high of $93.18. The stock’s 50-day moving average is currently $78.08. The company has a market cap of $4.696 billion and a price-to-earnings ratio of 65.17.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.